Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. 2001

L L Xu, and Y P Su, and R Labiche, and T Segawa, and N Shanmugam, and D G McLeod, and J W Moul, and S Srivastava
Center for Prostate Disease Research (CPDR), Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.

Quantitative expression profile of androgen-regulated genes (ARGs) was evaluated in the hormone-responsive prostate cancer cell line LNCaP by serial analysis of gene expression (SAGE). A total of 83,489 SAGE tags representing 23,448 known genes or expressed sequence tags (ESTs) and 1,655 potentially novel sequences have unraveled the transcriptome of LNCaP cells, the most common cell line used in prostate cancer research. Comparison of transcripts between control and R1881-treated LNCaP cells revealed the induction of 136 genes and repression of 215 genes in response to androgen (p < 0.05). Strikingly, a high fraction ( approximately 90%) of ARGs identified in our study has not been described as ARGs previously. A number of prostate-specific transcription factors were among the ARGs identified here. Classification of the ARGs on the basis of biochemical functions revealed that a great majority of ARGs identified in our experimental system appear to be involved in regulation of transcription, splicing, ribosomal biogenesis, mitogenesis, bioenergetics and redox processes. One of the novel aspects of androgen signaling included androgen regulation of genes involved in DNA repair/recombination process. By comparing our LNCaP-C and LNCaP-T SAGE libraries with SAGE tag libraries available at the NCBI-SAGE website, we have identified >200 potential prostate specific/abundant transcripts. The discovery of new prostate-specific genes and ARGs provides a unique opportunity to determine the role of these genes in prostate cell growth, differentiation and tumorigenesis.

UI MeSH Term Description Entries
D008297 Male Males
D009928 Organ Specificity Characteristic restricted to a particular organ of the body, such as a cell type, metabolic response or expression of a particular protein or antigen. Tissue Specificity,Organ Specificities,Specificities, Organ,Specificities, Tissue,Specificity, Organ,Specificity, Tissue,Tissue Specificities
D011467 Prostate A gland in males that surrounds the neck of the URINARY BLADDER and the URETHRA. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM. Prostates
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000728 Androgens Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. Androgen,Androgen Receptor Agonist,Androgen Effect,Androgen Effects,Androgen Receptor Agonists,Androgenic Agents,Androgenic Compounds,Agents, Androgenic,Agonist, Androgen Receptor,Agonists, Androgen Receptor,Compounds, Androgenic,Effect, Androgen,Effects, Androgen,Receptor Agonist, Androgen,Receptor Agonists, Androgen
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015741 Metribolone A synthetic non-aromatizable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors. Methyltrienolone,17 beta-Hydroxy-17 alpha-methylestra-4,9,11-trien-3-one,R-1881,R1881,Ru-1881,R 1881,Ru 1881,Ru1881

Related Publications

L L Xu, and Y P Su, and R Labiche, and T Segawa, and N Shanmugam, and D G McLeod, and J W Moul, and S Srivastava
March 2000, The Journal of urology,
L L Xu, and Y P Su, and R Labiche, and T Segawa, and N Shanmugam, and D G McLeod, and J W Moul, and S Srivastava
June 2002, Carcinogenesis,
L L Xu, and Y P Su, and R Labiche, and T Segawa, and N Shanmugam, and D G McLeod, and J W Moul, and S Srivastava
August 2004, Endocrinology,
L L Xu, and Y P Su, and R Labiche, and T Segawa, and N Shanmugam, and D G McLeod, and J W Moul, and S Srivastava
September 2012, Molecular medicine reports,
L L Xu, and Y P Su, and R Labiche, and T Segawa, and N Shanmugam, and D G McLeod, and J W Moul, and S Srivastava
December 1998, Cancer research,
L L Xu, and Y P Su, and R Labiche, and T Segawa, and N Shanmugam, and D G McLeod, and J W Moul, and S Srivastava
February 1997, Seminars in cancer biology,
L L Xu, and Y P Su, and R Labiche, and T Segawa, and N Shanmugam, and D G McLeod, and J W Moul, and S Srivastava
May 2009, Oncogene,
L L Xu, and Y P Su, and R Labiche, and T Segawa, and N Shanmugam, and D G McLeod, and J W Moul, and S Srivastava
May 1996, The Biochemical journal,
L L Xu, and Y P Su, and R Labiche, and T Segawa, and N Shanmugam, and D G McLeod, and J W Moul, and S Srivastava
January 2013, International journal of molecular medicine,
L L Xu, and Y P Su, and R Labiche, and T Segawa, and N Shanmugam, and D G McLeod, and J W Moul, and S Srivastava
December 2007, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!